Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?
Magdalena Kaczor(Children's Memorial Health Institute), Dorota Wesół‐Kucharska(Children's Memorial Health Institute), Dariusz Rokicki(Children's Memorial Health Institute), Elżbieta Ciara(Children's Memorial Health Institute), Barbara Piątosa(Children's Memorial Health Institute), Milena Greczan(Children's Memorial Health Institute), Karolina Kierus(Medical University of Białystok), Ewa Ehmke vel Emczyńska‐Seliga(Children's Memorial Health Institute), Janusz Książyk(Children's Memorial Health Institute)
Cited by 20
Related Papers
Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia
|Journal of the American Society of Nephrology|2015|284
New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre
|Journal of Translational Medicine|2016|233
Clinical implementation of RNA sequencing for Mendelian disease diagnostics
|Genome Medicine|2022|215
Biallelic mutations in CYP24A1 or SLC34A1 as a cause of infantile idiopathic hypercalcemia (IIH) with vitamin D hypersensitivity: molecular study of 11 historical IIH cases
|Journal of Applied Genetics|2017|94
Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations
|European Journal of Human Genetics|2001|71